PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-19.42%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
-49.76%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-230.13%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-230.13%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-185.65%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-184.62%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-184.62%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
1.23%
Share count expansion well above ADI's 0.47%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
1.23%
Slight or no buyback while ADI is reducing diluted shares. John Neff might consider the competitor’s approach more shareholder-friendly.
-1.21%
Dividend reduction while ADI stands at 0.00%. Joel Greenblatt would question the firm’s cash flow stability or capital allocation decisions.
392.44%
OCF growth above 1.5x ADI's 1.45%. David Dodd would confirm a clear edge in underlying cash generation.
131.24%
FCF growth above 1.5x ADI's 40.84%. David Dodd would verify if the firm’s strategic investments yield superior returns.
-15.41%
Negative 10Y revenue/share CAGR while ADI stands at 159.56%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
-28.11%
Negative 5Y CAGR while ADI stands at 87.09%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-17.91%
Negative 3Y CAGR while ADI stands at 57.47%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
1951.34%
10Y OCF/share CAGR above 1.5x ADI's 616.36%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
200.68%
Below 50% of ADI's 1824.28%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
65.62%
3Y OCF/share CAGR under 50% of ADI's 173.65%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
12.15%
Below 50% of ADI's 852.37%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
-319.46%
Negative 5Y net income/share CAGR while ADI is 119.78%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-430.85%
Negative 3Y CAGR while ADI is 84.68%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
352.70%
10Y equity/share CAGR in line with ADI's 361.95%. Walter Schloss might see both benefiting from stable profitability and moderate payout ratios over the decade.
150.63%
5Y equity/share CAGR at 50-75% of ADI's 234.56%. Martin Whitman would question a shortfall in capital accumulation vs. the competitor.
85.64%
3Y equity/share CAGR similar to ADI's 93.91%. Walter Schloss sees both having parallel profitability or reinvestment over 3 years.
-79.28%
Cut dividends over 10 years while ADI stands at 0.00%. Joel Greenblatt suspects a weaker ability to return capital vs. the competitor.
-2.78%
Negative 5Y dividend/share CAGR while ADI stands at 0.00%. Joel Greenblatt sees a weaker commitment to dividends vs. a competitor that might be growing them.
-2.08%
Negative near-term dividend growth while ADI invests at 0.00%. Joel Greenblatt sees a weaker short-term distribution policy unless justified by strategic spending.
-14.48%
Both reduce receivables yoy. Martin Whitman suspects a shift in the entire niche’s credit approach or softer demand.
-8.31%
Both reduce inventory yoy. Martin Whitman suspects a broader move to lean operations or industry slowdown in demand.
-3.13%
Negative asset growth while ADI invests at 2.31%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-3.76%
We have a declining book value while ADI shows 3.83%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-2.28%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
-7.62%
Our R&D shrinks while ADI invests at 2.56%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
14.94%
We expand SG&A while ADI cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.